Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer.

CONCLUSION: Our data suggest that HIPEC can be safely introduced in the upfront therapy of advanced ovarian cancer.
PMID: 30300042 [PubMed - as supplied by publisher]

Source: International Journal of Hyperthermia - October 10, 2018 Category: Internal Medicine Tags: Int J Hyperthermia Source Type: research